Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Comment by narmacon Jun 02, 2022 8:18am
302 Views
Post# 34725805

RE:Q&A with Sarah Re, May 9 2022 News Release

RE:Q&A with Sarah Re, May 9 2022 News Release,,you are a tuff one GV,,,good contact,,,,,and of course they refuse to comment and or provide the material data which has effected share price. The market is in the know,,,,,they have info around the C19 trial,,,,,,that trial was only to test shareholders patience,,,,,as we all know this team of misfits couldnt organize a one car funeral,,,,,,,its so sad its comical,,,,,,however we will  grasp at other straws,,,makes the team happy and their personal wealth greater,,,,,,,,thumbs in their bums and proud of it!!!...the inactivity has become part of their culture,,,,,,and if it has any talent within the confines of its walls,,it sure is a waste to them and to humanity......ugly situation all around imo!
<< Previous
Bullboard Posts
Next >>